The Classic Stack, Explained by Someone Who Actually Prescribes It
Dr. Ashley Froese walks through what many peptide practitioners consider the foundational peptide combination: CJC-1295 and Ipamorelin. If you have spent any time reading about peptides online, you have probably seen these two names mentioned together dozens of times. But most of what circulates on forums and social media is either incomplete or wrong. Having a physician who uses this combination in clinical practice break it down is exactly what the conversation needs.
Let us start with what each peptide does individually before explaining why they work better together. CJC-1295 is a growth hormone releasing hormone (GHRH) analog. Your hypothalamus naturally produces GHRH, which tells your pituitary gland to release growth hormone. CJC-1295 mimics this signal but lasts much longer in the body. The version most commonly used in clinical practice is CJC-1295 with DAC (Drug Affinity Complex), which binds to albumin in the blood and extends the half-life to about 6-8 days. Without DAC, the half-life is only about 30 minutes.
Ipamorelin is a growth hormone secretagogue, meaning it also stimulates GH release, but through a completely different receptor. It acts on the ghrelin receptor (GHS-R) in the pituitary. Think of it as a different doorbell ringing at the same house. The pituitary gets the message to release growth hormone through two separate signaling pathways simultaneously.
This dual-pathway stimulation is why the combination works better than either peptide alone. CJC-1295 provides a sustained baseline elevation in GH-releasing signals. Ipamorelin provides sharper, pulse-like spikes. Together, they produce a growth hormone release pattern that closely mimics what a healthy young body produces naturally, with regular pulses superimposed on a slightly elevated baseline.
What Growth Hormone Optimization Actually Does
Dr. Froese explains that growth hormone is not just about growth. In adults, GH plays critical roles in body composition, sleep quality, tissue repair, immune function, and metabolism. GH levels peak during puberty and decline steadily after age 30, dropping roughly 14% per decade. By 60, most adults are producing a small fraction of their youthful GH output. This decline correlates with increased body fat (especially visceral fat), decreased muscle mass, thinner and less elastic skin, slower recovery from injury and exercise, and poorer sleep quality.
The goal of secretagogue therapy is not to achieve the growth hormone levels of a teenager. It is to restore levels to a healthy range that supports optimal function. Froese targets IGF-1 (insulin-like growth factor 1, the main downstream marker of GH activity) in the upper third of the age-adjusted reference range. Going higher than that increases the risk of side effects without proportional benefit.
The practical benefits patients report, and that Froese sees in her practice, follow a roughly consistent timeline. Sleep improvement comes first, usually within the first 1-2 weeks. Growth hormone is released primarily during deep sleep (stage 3 NREM), and the peptide combination appears to increase both the quantity and quality of deep sleep. Patients describe more vivid dreams, easier sleep onset, and feeling more rested upon waking.
Body composition changes follow over 4-12 weeks. Fat loss, particularly from the midsection, and gradual improvement in muscle tone are typical. These changes are not as dramatic as what you would see with direct HGH injection at supraphysiological doses, but they are meaningful and come without most of the side effects associated with exogenous GH. Skin quality improvement, often described as thicker, more hydrated, and more elastic skin, appears over 3-6 months.
Dosing Protocols: What Froese Uses in Practice
Froese outlines her standard protocol, which is representative of what most experienced peptide clinicians use. She prescribes CJC-1295 with Ipamorelin as a combined preparation (many compounding pharmacies provide them pre-mixed in a single vial). Standard dosing is 300mcg of the combination injected subcutaneously at bedtime, five days per week with two days off.
The bedtime dosing is strategic. Growth hormone is naturally released in the first 90 minutes of sleep, during the initial deep sleep phase. Injecting the peptide combination 20-30 minutes before sleep amplifies this natural pulse. Some practitioners use a second injection in the morning on an empty stomach, but Froese finds the once-daily bedtime protocol sufficient for most patients and easier to maintain long-term.
The five-on, two-off cycling prevents receptor desensitization. GH receptors can become less responsive with continuous stimulation, a phenomenon common to many receptor-mediated drug effects. The two rest days per week help maintain receptor sensitivity. Some practitioners use different cycling patterns, like three weeks on and one week off, but Froese finds the daily cycling approach produces more consistent results.
She runs the initial protocol for 3-6 months, then reassesses based on blood work and symptom improvement. Some patients continue long-term with the same protocol. Others cycle off for a few months and restart. There is no definitive evidence for the optimal long-term strategy, so clinical judgment and patient preference guide the decision.
Side Effects and Risks: Honest Assessment
Froese covers the side effect profile thoroughly. The most common side effect is water retention, which can manifest as slightly swollen fingers or a feeling of puffiness, especially in the first few weeks. This usually resolves as the body adjusts. If it persists, it may indicate the dose is too high.
Increased hunger is another common effect, which makes sense given that Ipamorelin acts on the ghrelin receptor (ghrelin being the "hunger hormone"). Some patients experience this strongly in the first few weeks, while others barely notice it. Managing this with adequate protein intake and meal timing helps.
Transient tingling or numbness in the hands (similar to carpal tunnel symptoms) can occur with growth hormone elevation. This is related to fluid shifts and is dose-dependent. If it happens, reducing the dose usually resolves it.
The more serious theoretical concerns involve insulin sensitivity and cancer risk. Growth hormone can worsen insulin sensitivity, particularly at higher levels. Froese monitors fasting insulin and glucose in all patients on GH secretagogue protocols and adjusts if she sees insulin resistance developing. The cancer concern is more theoretical. Growth hormone promotes cell proliferation, and some epidemiological studies have linked very high IGF-1 levels to increased cancer risk. Froese keeps IGF-1 within the physiological range (not supraphysiological) to mitigate this concern, and she does not prescribe GH secretagogues to patients with active cancer or a recent cancer history.
Who Is a Good Candidate and Who Is Not
Froese defines her ideal patient: someone over 35 with symptoms of GH decline (poor sleep, increasing body fat despite consistent exercise, slow recovery, low energy) whose blood work confirms low IGF-1 levels. They should have stable metabolic health without uncontrolled diabetes or active cancer. They should be willing to commit to the injection protocol, the blood work monitoring, and the lifestyle factors (exercise, nutrition, sleep hygiene) that make the peptides work optimally.
Poor candidates include anyone with active malignancy, severe uncontrolled diabetes, or a history of pituitary tumors. Pregnant or nursing women should not use GH secretagogues. People looking for a quick fix without willingness to address diet, exercise, and sleep are also poor candidates, not because the peptides are dangerous for them, but because they will not get meaningful results and will waste money.
Lab Work and Monitoring: The Non-Negotiable Part
Before starting, Froese draws baseline IGF-1, fasting insulin, fasting glucose, HbA1c, complete metabolic panel, CBC, and thyroid panel. At 6 weeks, she repeats IGF-1 and fasting insulin. The IGF-1 level tells her whether the peptides are producing the desired GH elevation. The fasting insulin tells her whether metabolic safety is maintained.
At 12 weeks, she runs the full panel again. She also assesses subjective outcomes: sleep quality, energy levels, body composition changes, and exercise recovery. If blood work is favorable and the patient is experiencing benefits, she continues the protocol. If IGF-1 has not moved despite consistent dosing, she considers whether the peptide product quality might be an issue (a real possibility with compounded products) or whether the patient pituitary response is limited.
Froese presentation is practical, evidence-aware, and appropriately cautious. She does not oversell the combination but clearly believes in it based on her clinical experience. For anyone considering GH secretagogue therapy, this video provides a solid, physician-guided foundation for understanding what to expect and how to proceed safely.